[go: up one dir, main page]

MX2018000202A - Analogos de cisteamina resistentes a la ado y sus usos. - Google Patents

Analogos de cisteamina resistentes a la ado y sus usos.

Info

Publication number
MX2018000202A
MX2018000202A MX2018000202A MX2018000202A MX2018000202A MX 2018000202 A MX2018000202 A MX 2018000202A MX 2018000202 A MX2018000202 A MX 2018000202A MX 2018000202 A MX2018000202 A MX 2018000202A MX 2018000202 A MX2018000202 A MX 2018000202A
Authority
MX
Mexico
Prior art keywords
ado
diseases
resistant
analogs
cysteamine
Prior art date
Application number
MX2018000202A
Other languages
English (en)
Other versions
MX384804B (es
Inventor
Gourdet Benoit
C Zankel Todd
Unitt John
Phillips Timothy
DUFFY Loma
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of MX2018000202A publication Critical patent/MX2018000202A/es
Publication of MX384804B publication Critical patent/MX384804B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/26—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/30—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención está dirigida a análogos de cisteamina resistentes a la ADO para usarse en métodos para tratar enfermedades para las cuales las cisteamida está indicada, en particular cistinosis, enfermedad de hígado graso, fibrosis, enfermedades trombóticas, trastornos relacionados con MECP-2, enfermedades hereditarias en las mitocondrias, enfermedades o trastornos neurológicos, inflamación y cáncer.
MX2018000202A 2015-07-02 2016-07-01 Analogos de cisteamina resistentes a la ado y sus usos. MX384804B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187939P 2015-07-02 2015-07-02
US201562387337P 2015-12-23 2015-12-23
PCT/US2016/040637 WO2017004485A1 (en) 2015-07-02 2016-07-01 Ado-resistant cysteamine analogs and uses thereof

Publications (2)

Publication Number Publication Date
MX2018000202A true MX2018000202A (es) 2018-06-27
MX384804B MX384804B (es) 2025-03-14

Family

ID=56511899

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000202A MX384804B (es) 2015-07-02 2016-07-01 Analogos de cisteamina resistentes a la ado y sus usos.
MX2021008819A MX2021008819A (es) 2015-07-02 2018-01-08 Analogos de cisteamina resistentes a la ado y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008819A MX2021008819A (es) 2015-07-02 2018-01-08 Analogos de cisteamina resistentes a la ado y sus usos.

Country Status (14)

Country Link
US (2) US10906904B2 (es)
EP (1) EP3316877B1 (es)
JP (2) JP2018525350A (es)
KR (1) KR20180034466A (es)
CN (1) CN108289867A (es)
AU (2) AU2016288230A1 (es)
BR (1) BR112017028448A2 (es)
CA (1) CA2991099A1 (es)
ES (1) ES2770113T3 (es)
IL (1) IL256553B (es)
MX (2) MX384804B (es)
RU (2) RU2022103033A (es)
TW (2) TW202247838A (es)
WO (1) WO2017004485A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028448A2 (pt) 2015-07-02 2018-08-28 Horizon Orphan Llc análogos de cisteamina resistentes a ado e usos dos mesmos
CA3097510A1 (en) * 2017-04-24 2018-11-01 Mercaptor Discoveries, Inc. Use of thiol compounds to treat neurological disease
AU2019228134B2 (en) * 2018-03-01 2022-03-03 Obvia Pharmaceuticals Ltd Novel aminothiol reduction of ischemia-reperfusion-induced cell death
GB201806095D0 (en) * 2018-04-13 2018-05-30 Ucl Business Plc Metabolisable pH sensitive polymersomes
US20210113496A1 (en) * 2018-04-25 2021-04-22 Horizon Orphan Llc Methods of Treating Excitotoxicity Disorders
GB2581362A (en) 2019-02-14 2020-08-19 Univ Of Sunderland Chemical synthesis
EP4303224A4 (en) * 2021-03-03 2025-02-19 Tohoku University PROTEIN FOLDING AGENTS

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834785A (en) 1954-11-16 1958-05-13 Lakeside Lab Inc N-substituted-3-thiol piperidines and thioesters thereof
GB780027A (en) 1955-01-20 1957-07-31 Schering Corp 3-piperidyl ethers and thioethers
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
FR2549064B1 (fr) 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines utiles pour la preparation de nouveaux medicaments antimicrobiens et leur preparation
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
DE3586746D1 (de) 1984-04-03 1992-11-19 Takeda Chemical Industries Ltd Lipidderivate, ihre produktion und verwendung.
PH22302A (en) 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5071846A (en) 1987-07-01 1991-12-10 Janssen Pharmaceutica N.V. Anti-hystaminic [(bicyclic heterocyclyl) methyl and --hetero] substituted hexahydro-1H-azepines and pyrrolidines
US5151424A (en) 1987-07-01 1992-09-29 Janssen Pharmaceutica N.V. Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines
US4988689A (en) 1987-07-01 1991-01-29 Janssen Pharmaceutica N.V. ((Pharmacologically active bicyclic heterocyclic)methyl and -heteroatom) substituted hexahydro-1H-azepines and pyrrolidines
GB2206879A (en) 1987-07-07 1989-01-18 May & Baker Ltd Novel pristinamycin IIB derivatives, their preparation and pharmaceutical compositions containing them
DE3808678A1 (de) 1988-03-11 1989-09-21 Schering Ag Anellierte imino-azole, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung
EP0339406A1 (en) 1988-04-19 1989-11-02 Hokuriku Pharmaceutical Co.,Ltd Quinoline-3-carboxylic acid derivatives, process for preparing the same, and composition exhibiting excellent antibacterial effect containing the same
FR2635524B1 (fr) 1988-08-19 1992-04-24 Adir Nouveaux derives de benzopyrrolidinone, leur procede de preparation et les compositions pharmaceutiques les renfermant
US5272150A (en) 1989-04-07 1993-12-21 Janssen Pharmaceutica N.V. Hydroxyalkylfuranyl derivatives
CA2015949A1 (en) 1989-05-22 1990-11-22 Yasuo Ito Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
JPH03118319A (ja) * 1989-09-30 1991-05-20 Green Cross Corp:The 抗炎症剤、胃液分泌抑制剤または活性酸素産生抑制剤
FR2655649B1 (fr) 1989-12-12 1994-07-08 Adir Nouveaux derives de la piperidine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5217980A (en) 1990-07-19 1993-06-08 Janssen Pharmaceutica N.V. Oxazolyl and piperidinyl substituted benimidazolyl compounds
TW198027B (es) 1990-08-26 1993-01-11 Sankyo Co
KR950005301B1 (ko) 1990-09-04 1995-05-23 주식회사대웅제약 신규한 퀴놀론 카르복실산 유도체
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
PT100914A (pt) * 1991-09-30 1993-10-29 Jess G Thoene Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
ATE181735T1 (de) 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
FR2705346B1 (fr) 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
US5783703A (en) 1993-07-01 1998-07-21 Lederle (Japan), Ltd. Sulfur-containing compounds method for their use and prodction
EP0804434A1 (en) 1994-08-02 1997-11-05 MERCK SHARP &amp; DOHME LTD. Azetidine, pyrrolidine and piperidine derivatives
US5821371A (en) 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
EP0717042B1 (en) 1994-12-12 2001-05-23 Wyeth Lederle Japan LTD. Process for preparing 1-(4,5-Dihydro-2-thiazolyle)-3-azetidine thiol derivatives
JP3724854B2 (ja) 1995-09-11 2005-12-07 ワイス株式会社 １−アザビシクロ［１．１．０］ブタンの製造法
GB9523243D0 (en) 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
JP3209679B2 (ja) 1996-04-05 2001-09-17 日本ワイスレダリー株式会社 ジスルフィド化合物およびその製造法
GB9610979D0 (en) 1996-05-24 1996-07-31 Merck Sharp & Dohme Therapeutic agents
JPH1143792A (ja) 1997-07-23 1999-02-16 Asahi Kagaku Kogyo Co Ltd 酸洗促進剤、酸洗促進剤を含んだ酸洗液組成物およびこれを用いる酸洗方法
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
WO1999036403A1 (en) 1998-01-13 1999-07-22 The Trustees Of The University Of Pennsylvania Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
AU5450199A (en) 1998-09-10 2000-04-03 Wyeth Lederle Japan, Ltd. Carbapenem compounds
WO2000021565A1 (en) * 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
JP2002528495A (ja) * 1998-10-30 2002-09-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法
BR9806353A (pt) * 1998-11-10 2000-06-20 Univ Minas Gerais Processo para a preparação e aplicação farmacológica de novos beta-aminotióis e respectivos sais
JP2001131067A (ja) * 1999-08-26 2001-05-15 Sankyo Co Ltd 血小板凝集抑制剤又は動脈硬化進展抑制剤
US6455573B1 (en) 2000-01-07 2002-09-24 Simon Fraser University Glycosidase inhibitors and methods of synthesizing same
US6369243B1 (en) 2000-01-18 2002-04-09 The Regents Of The Univerisity Of California Chemical transformation of substrates using nonmetallic, organic catalyst compositions
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
MXPA03000368A (es) 2000-07-19 2004-09-13 Hoffmann La Roche Derivados de pirrolidina como inhibidores de metalproteasa.
AU2002354901A1 (en) 2001-07-16 2003-03-03 Edward Hogestatt Compounds with analgesic, antipyretic and/or anti-inflammatory activity
JP2003183281A (ja) 2001-12-21 2003-07-03 Wyeth Lederle Japan Ltd カルバペネム化合物
JP2003183280A (ja) 2001-12-21 2003-07-03 Wyeth Lederle Japan Ltd カルバペネム化合物
US7408067B2 (en) 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
US6743864B2 (en) 2002-03-12 2004-06-01 Basell Poliolefine Italia S.P.A. Polyolefin compositions having high tenacity
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
SE0300812D0 (sv) 2003-03-24 2003-03-24 Karolinska Innovations Ab Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect
JP2006523692A (ja) 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
US7314959B2 (en) * 2003-08-07 2008-01-01 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
ATE450535T1 (de) 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
EP2289498A1 (en) * 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
EP1541143A1 (en) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
KR101329369B1 (ko) 2003-12-19 2013-11-14 오메가 바이오 파마(아이.피.3) 리미티드 당뇨 치료용 조성물 및 방법
CA2565250C (en) 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
JP2006001841A (ja) 2004-06-15 2006-01-05 Sumitomo Chemical Co Ltd 含窒素へテロ環化合物の製造方法
PL1637141T3 (pl) 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101107217A (zh) 2005-01-13 2008-01-16 惠氏公司 用于制备氨基乙氧基苄醇类的方法
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN101196230A (zh) 2006-01-06 2008-06-11 赵文利 机械动力多司调制技术
ES2774755T3 (es) 2006-01-27 2020-07-22 Univ California Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
TWI389917B (zh) 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
CN101663290A (zh) * 2007-04-19 2010-03-03 Ucb医药有限公司 包含环丁氧基的组胺h3受体配体
US20090163705A1 (en) 2007-05-21 2009-06-25 Alnylam Pharmaceuticals, Inc. Cationic lipids
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
DE102008032561A1 (de) 2007-07-16 2009-01-22 Basf Se Verfahren und Mischung zur Reinigung von Alkinen
US8026285B2 (en) 2007-09-04 2011-09-27 Bezwada Biomedical, Llc Control release of biologically active compounds from multi-armed oligomers
DK2214480T3 (da) 2007-11-30 2013-07-08 Univ California Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter
EP2268638A1 (en) 2008-03-31 2011-01-05 Evotec AG Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010015815A2 (en) 2008-08-05 2010-02-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010026113A1 (en) 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
WO2010041964A1 (en) 2008-10-09 2010-04-15 Victoria Link Limited Methods for the preparation of alkenylamines, cyclic carbamates or dithiocarbamates, and aminoalcohols or aminothiols
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
US20120165304A1 (en) 2008-11-27 2012-06-28 Boehringer Ingelheim International Gmbh 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
JP2012532834A (ja) 2009-07-11 2012-12-20 バイエル ファーマ アクチエンゲゼルシャフト シクロアルキル基を用いる放射性標識方法
WO2011061214A1 (en) 2009-11-18 2011-05-26 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
TWI485153B (zh) 2010-01-13 2015-05-21 Sanofi Aventis ２，５，７－經取代唑并嘧啶衍生物
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
AU2011322715A1 (en) * 2010-10-25 2013-05-23 Centre National De La Recherche Scientifique Treatment of MeCP2-associated disorders
US20120309785A1 (en) * 2010-12-03 2012-12-06 Bill Piu Chan Use of Cysteamine in Treating Parkinson's Disease
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
WO2013024376A1 (en) 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
BR112014009789A2 (pt) * 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
JP6411215B2 (ja) * 2011-11-22 2018-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 虚血傷害を治療するためのシステアミンおよび／またはシスタミン
EP2601940A1 (en) * 2011-12-05 2013-06-12 Lacer, S.A. (4-mercapto-piperidin-4-yl)-aminoacetic acid derivatives, pharmaceutical compositions and uses thereof
MX2016005858A (es) * 2013-11-06 2016-08-11 Raptor Pharmaceuticals Inc Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales.
AU2015239108A1 (en) 2014-04-01 2016-10-20 Institut Jules Bordet New strategies for treating melanoma
EA201691988A1 (ru) 2014-05-19 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
BR112017028448A2 (pt) 2015-07-02 2018-08-28 Horizon Orphan Llc análogos de cisteamina resistentes a ado e usos dos mesmos

Also Published As

Publication number Publication date
AU2021200321A1 (en) 2021-03-18
JP2018525350A (ja) 2018-09-06
EP3316877B1 (en) 2019-10-30
KR20180034466A (ko) 2018-04-04
AU2016288230A1 (en) 2018-01-25
ES2770113T3 (es) 2020-06-30
TW202247838A (zh) 2022-12-16
EP3316877A1 (en) 2018-05-09
IL256553A (en) 2018-02-28
US20170002004A1 (en) 2017-01-05
JP2021152087A (ja) 2021-09-30
TW201713324A (zh) 2017-04-16
RU2022103033A (ru) 2022-04-01
WO2017004485A1 (en) 2017-01-05
TWI759267B (zh) 2022-04-01
MX2021008819A (es) 2021-08-24
US11505550B2 (en) 2022-11-22
BR112017028448A2 (pt) 2018-08-28
CN108289867A (zh) 2018-07-17
IL256553B (en) 2021-03-25
RU2766579C2 (ru) 2022-03-15
US20220024920A1 (en) 2022-01-27
RU2018103901A (ru) 2019-08-05
US10906904B2 (en) 2021-02-02
RU2018103901A3 (es) 2020-05-25
CA2991099A1 (en) 2017-01-05
MX384804B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
MX2018000202A (es) Analogos de cisteamina resistentes a la ado y sus usos.
PL3349783T3 (pl) Kompozycje i sposoby do leczenia chorób
IL267210A (en) Amino acid compounds and methods for treating muscle diseases and disorders
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
IL260352B (en) Methods and preparations for the treatment of neurological disease
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
IL262348A (en) Preparations for the treatment of excessive radiation disorders
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
IL320533A (en) Methods and compositions for treating disorders and diseases involving RDH12
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3538219A4 (en) TOPICAL COMPOSITION FOR TREATING ACNE
MX2017014782A (es) Metodo para el tratamiento de enfermedad neurologica.
MX2022015456A (es) Composiciones de maca y metodos de uso.
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3215222A4 (en) Methods of treating huntington&#39;s disease using cysteamine compositions
PH12017501694B1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
ZA201806103B (en) Compositions and methods for the treatment of sinus disease and disorders
ZA201801945B (en) Compositions and methods for the treatment of parkinson&#39;s disease
EP3371181A4 (en) COMPOSITIONS AND METHODS FOR REGULATING DISORDERS AND DISEASES ASSOCIATED WITH CANCER
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
HK40009011A (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders